Vivoryon Therapeutics N.V.
VVY.AS · AMS
6/30/2025 | 12/31/2024 | 6/30/2024 | 12/31/2023 | |
|---|---|---|---|---|
| Valuation | ||||
| PEG Ratio | 0.08 | 0.04 | 0.03 | -0.04 |
| FCF Yield | -11.80% | -11.37% | -26.57% | -0.63% |
| EV / EBITDA | -6.09 | -6.19 | -2.53 | -10.33 |
| Quality | ||||
| ROIC | -105.36% | -71.48% | -90.26% | -66.15% |
| Gross Margin | 0.00% | 0.00% | 0.00% | 114.50% |
| Cash Conversion Ratio | 0.82 | 0.84 | 0.98 | 0.07 |
| Growth | ||||
| Revenue 3-Year CAGR | – | – | – | – |
| Free Cash Flow Growth | 23.42% | 55.82% | -953.05% | 93.78% |
| Safety | ||||
| Net Debt / EBITDA | 0.87 | 1.35 | 1.11 | 1.06 |
| Interest Coverage | -230.13 | -111.75 | -627.68 | -604.83 |
| Efficiency | ||||
| Inventory Turnover | 0.00 | 0.00 | 0.00 | 0.00 |
| Cash Conversion Cycle | -1,263.70 | -1,234.46 | -1,806.16 | -508.42 |